Literature DB >> 10692674

Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities.

M Okada1, T Okamoto, Y Takemoto, A Kanamaru, E Kakishita.   

Abstract

To investigate the pathogenesis of immunological abnormalities (IA) in myelodysplastic syndrome (MDS), we examined B cells for their ability to produce cytokine and their X chromosome inactivation pattern (XCIP). An IA was defined as being positive for at least one autoimmune laboratory test (e.g. antinuclear antibody, rheumatoid factor). Seventy-three MDS patients [65 with refractory anemia (RA), 3 with RA with excess blasts (RAEB), and 5 with RAEB in transformation] were examined; 47 had IA and 26 had no IA. To examine the function of B cells in MDS, the production of interleukin (IL)-6 and IL-10 was measured in cultures of purified B cells with or without stimulators. Both IL-6 and IL-10 production rates in patients with IA were significantly higher than in patients without IA and normal controls. The skewing of XCIP of B cells was analyzed by using the polymerase chain reaction, and the skewing rate of B cell XCIP was quantitatively assayed by compared to control T lymphocytes. The skewing rate of B cells was higher in patients with IA than in those without IA and normal controls. Therefore, a small population of B cells in patients with IA might be derived from MDS clones, and be associated with the induction of IA. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692674     DOI: 10.1159/000040985

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

Review 1.  Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.

Authors:  A John Barrett; Elaine Sloand
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

2.  Coombs' test positive autoimmune hemolytic anemia accompanied by myelodysplastic syndrome that became Coombs' test negative after azacitidine administration.

Authors:  Shinya Yamada; Sayaka Kajikawa; Noriharu Nakagawa; Yukio Kondo; Hirokazu Okumura
Journal:  Ann Hematol       Date:  2021-08-27       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.